Healthy Q2 and H1; resulting in consecutive guidance upgrade
04/08/22 -"DiaSorin released healthy Q2 results. While, as expected, non-COVID-19 offerings continued to do well, slower-than-expected moderation in COVID-19 testing sales was a pleasant surprise – also ..."
Pages
57
Language
English
Published on
04/08/22
You may also be interested by these reports :
17/08/22
Considering the downward revision to the full-year outlook (in reported terms), due to external challenges like tougher FX, high inflation and supply ...
17/08/22
Demant reported soft Q2 results. While, like Sonova, the management also downgraded is full-year outlook, the brewing slowdown in the US hearing aid ...
16/08/22
After many quarters of nervousness/disappointments, Philips today announced a change in CEO, effective mid-October 2022. This was perhaps inevitable ...
16/08/22
Following Sonova and Demant’s guidance downgrades, there has been a panic across the board with all hearing aid stocks in our coverage down 4-14%. ...